Gui-Ling Chen

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 9

Top Topics

Lymph Node Metastasis

Gestational Age

Placebo Controlled

Top Venues

Rheumatology and therapy

Diabetes, obesity & metabolism

This page only lists publications with an associated author ORCID identifier.

Publications

Gui-Ling Chen, Yang Liu, Xue-Feng Gao, Kai-Qi Wu, Yun-Kai Yang, Yong Chen, Cong-Gao Peng, Ting-Han Jin, Yu-Bao Huang, Yao-Wen Zhang, Jing Su, Qi Jiang, Tong Guo, Jie Zhao, Xiang-Nan Peng, Jing-Yu Peng, Si-Xiu Li, Yong-Li Sun, Hong-Mei Zhang, Yan-Li Fu, Dan Luo, Yaru Ma, Zhen-Wei Shen, Yun-Tao Zhang, Zhang-Fei Shou
Safety, tolerability, pharmacokinetic, pharmacodynamic and immunogenicity profiles of Exendin-4-IgG4-Fc in healthy subjects: A phase 1, single-centre, randomized, double-blind, dose escalation study. Diabetes, obesity & metabolism (2024)
Gui-Ling Chen, Yang Liu, Xue-Feng Gao, Kai-Qi Wu, Yun-Kai Yang, Yong Chen, Cong-Gao Peng, Ting-Han Jin, Yu-Bao Huang, Yao-Wen Zhang, Jing Su, Qi Jiang, Tong Guo, Jie Zhao, Xiang-Nan Peng, Jing-Yu Peng, Si-Xiu Li, Yong-Li Sun, Hong-Mei Zhang, Yan-Li Fu, Dan Luo, Yaru Ma, Zhen-Wei Shen, Yun-Tao Zhang, Zhang-Fei Shou
Safety, tolerability, pharmacokinetic, pharmacodynamic and immunogenicity profiles of Exendin-4-IgG4-Fc in healthy subjects: A phase 1, single-centre, randomized, double-blind, dose escalation study. Diabetes, obesity & metabolism 26 (4) (2024)
Zhen-Wei Shen, Kai-Qi Wu, Ting-Han Jin, Jie Zhao, Qi Jiang, Tong Guo, Min Fang, Gui-Ling Chen
Pharmacokinetics, Safety, and Immunogenicity of Intravenous and Subcutaneous Single-Dose QX002N Injection in Healthy Subjects: A Randomized, Open, Parallel, Single-Center, Phase I Study. Rheumatology and therapy (2024)
Zhen-Wei Shen, Kai-Qi Wu, Ting-Han Jin, Jie Zhao, Qi Jiang, Tong Guo, Min Fang, Gui-Ling Chen
Pharmacokinetics, Safety, and Immunogenicity of Intravenous and Subcutaneous Single-Dose QX002N Injection in Healthy Subjects: A Randomized, Open, Parallel, Single-Center, Phase I Study. Rheumatology and therapy 11 (4) (2024)
Zhen-Wei Shen, Kai-Qi Wu, Ting-Han Jin, Jie Zhao, Qi Jiang, Tong Guo, Min Fang, Gui-Ling Chen
Pharmacokinetics, Safety, and Immunogenicity of Intravenous and Subcutaneous Single-Dose QX002N Injection in Healthy Subjects: A Randomized, Open, Parallel, Single-Center, Phase I Study. Rheumatology and therapy 11 (4) (2024)
Gui-Ling Chen, Yang Liu, Xue-Feng Gao, Kai-Qi Wu, Yun-Kai Yang, Yong Chen, Cong-Gao Peng, Ting-Han Jin, Yu-Bao Huang, Yao-Wen Zhang, Jing Su, Qi Jiang, Tong Guo, Jie Zhao, Xiang-Nan Peng, Jing-Yu Peng, Si-Xiu Li, Yong-Li Sun, Hong-Mei Zhang, Yan-Li Fu, Dan Luo, Yaru Ma, Zhen-Wei Shen, Yun-Tao Zhang, Zhang-Fei Shou
Safety, tolerability, pharmacokinetic, pharmacodynamic and immunogenicity profiles of Exendin-4-IgG4-Fc in healthy subjects: A phase 1, single-centre, randomized, double-blind, dose escalation study. Diabetes, obesity & metabolism 26 (4) (2024)
Zhen-Wei Shen, Kai-Qi Wu, Ting-Han Jin, Jie Zhao, Qi Jiang, Tong Guo, Min Fang, Gui-Ling Chen
Pharmacokinetics, Safety, and Immunogenicity of Intravenous and Subcutaneous Single-Dose QX002N Injection in Healthy Subjects: A Randomized, Open, Parallel, Single-Center, Phase I Study. Rheumatology and therapy 11 (4) (2024)
Zhen-Wei Shen, Kai-Qi Wu, Ting-Han Jin, Jie Zhao, Qi Jiang, Tong Guo, Min Fang, Gui-Ling Chen
Pharmacokinetics, Safety, and Immunogenicity of Intravenous and Subcutaneous Single-Dose QX002N Injection in Healthy Subjects: A Randomized, Open, Parallel, Single-Center, Phase I Study. Rheumatology and therapy 11 (4) (2024)
Gui-Ling Chen, Yang Liu, Xue-Feng Gao, Kai-Qi Wu, Yun-Kai Yang, Yong Chen, Cong-Gao Peng, Ting-Han Jin, Yu-Bao Huang, Yao-Wen Zhang, Jing Su, Qi Jiang, Tong Guo, Jie Zhao, Xiang-Nan Peng, Jing-Yu Peng, Si-Xiu Li, Yong-Li Sun, Hong-Mei Zhang, Yan-Li Fu, Dan Luo, Yaru Ma, Zhen-Wei Shen, Yun-Tao Zhang, Zhang-Fei Shou
Safety, tolerability, pharmacokinetic, pharmacodynamic and immunogenicity profiles of Exendin-4-IgG4-Fc in healthy subjects: A phase 1, single-centre, randomized, double-blind, dose escalation study. Diabetes, obesity & metabolism 26 (4) (2024)